Marie Reilly

Marie Reilly

Professor Emeritus/Emerita
Visiting address: Nobels väg 12a, 17165 Stockholm
Postal address: C8 Medicinsk epidemiologi och biostatistik, C8 MEB III, 171 77 Stockholm

About me

  • Marie Reilly, BSc, MSc, PhD

    Ph.D. in Biostatistics (1991).University of Washington, Seattle, U.S.A.

    Biostatistician at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm. Professor from 2003.

    Education
    - PhD (Biostatistics, University of Washington, Seattle, USA, 1991)
    - MSc. (Mathematics & Statistics, University College Galway, Ireland, 1977)
    - BSc (Physics, University College Galway, Ireland, 1975)

    Academic honours, awards and prizes
    - Best non-US Paper Prize, Obs & Gyn journal, March 2013.
    - Best Paper Prize from International Society of Blood Transfusion, 2010
    - School of Public Health Outstanding Student Award (University of Washington, Seattle, 1989)
    - Donovan Thompson Graduate Student Award (University of Washington, 1988)
    - Sir Joseph Larmor Faculty Prize (National University of Ireland, Galway, 1975)

Research

  • Epidemiologic Design

    Text book "Controlled Epidemiological Studies", Chapman & Hall /CRC, 2023

    Statistical methods for extended design and analysis of "controlled" epidemiological studies, including:
    - two-stage designs
    - Re-use of case-control data for studying new outcomes
    - Estimation of absolute risk from nested case-control data
    - Variations of nested case-control designs using enriched or extreme sampling
    - self-controlled designs

    Perinatal Epidemiology
    - Maternal alloimmunization with specific antibodies from the Rhesus and non-Rhesus systems
    - Association of blood group with maternal outcome, including preeclampsia, pregnancy-associated hypertension and pregnancy-associated DVT/PE
    -Effect of maternal alloimmunization on pregnancy and neonatal outcomes using population registers and clinical cohort data
    - Development of prediction models for risk-stratification of pregnant women with regard to alloimmunization
    - risk factors for cervical insufficiency
    - association between infertility and cervical insufficiency, and potential modification by ART

    Infectious Diseases/Immunology
    - Studies of mother-to-child transmission of HIV, focusing on peptide responses from Elispot assays and Flow Cytometry data;
    Phase I/II randomized clinical trials of candidate HIV-vaccines in infants and adults
    - Studies of the effect of maternal antiretroviral treatment for HIV on passive transfer of antibodies to infants and on infant immunity to common infections (measles, rotavirus, pneumonia)
    - Investigation of growth curves of HIV-exposed uninfected infants before and after administration of an experimental vaccine, with a focus on role of breastfeeding and maternal antiretroviral treatment.
    - Development of statistical methodology to analyze Elispot responses, including (i) estimation of individual peptide effects from pooled peptide data and (ii) analysis of repeated Elispot assays from the same individual controlling for false discovery rate
    Design of software tools for exploring flow cytometry data

    Family Data
    - Investigation of the impact of truncated register data on epidemiological analyses of familial disease risk, with applications to the Swedish Inpatient Register and MultiGeneration Register.
    - Development of statistical models for joint estimation of risk to different family members of patients, and investigation of patterns of these familial risks over time.
    - Methods and software for smoothed hazard estimation

Teaching

  • Actively involved in there design and delivery of
    biostatistics courses to undergraduate medical students
    core courses for PhD students of epidemiology
    advanced courses for PhD students, post-doctoral scientists and health professionals.

Articles

All other publications

Grants

  • Design and analysis of more effective epidemiological studies for cancer research
    Swedish Cancer Society
    1 January 2017
    The major investments in the collection and measurement of biomarkers for cancer have generated an interest in more cost-effective designs of studies and more efficient use of the costly data generated. Fall control studies are a very well-used study design where cases of a disease are selected and compared to a selection of healthy controls. For an unusual disease, this is much more effective than following up a sizable amount of healthy individuals to ensure that enough disease cases occur during the follow-up. However, until recently, it was unusual to reuse already collected data from case-control studies. Our work develops methods that eliminate limitations and for case-control studies forward towards new and effective study designs. Our methods make it possible to calculate the prognosis or risk of other cancers using the data from case-control studies or from more cost-effective designs where the earliest cases are compared to the longest living controls. We focused on a number of different cancers where the costly information is collected / collected
    dose of radiation therapy and lung cancer, mammographic density and breast cancer, genetic biomarkers for lethal prostate cancer. As time and money is a limitation in itself, researchers continue to use case control and other designs for data collection. Data currently generated for these studies is currently not fully utilized. Our work is to develop methods and software that more cost-effectively utilize research data to estimate cancer risk and prognosis. This can in turn lead to a more optimal and more ethical use of the biological material that volunteers contributed to cancer research.
  • Design and analysis of more effective epidemiological studies for cancer research
    Swedish Cancer Society
    1 January 2016
    The major investments in the collection and measurement of biomarkers for cancer have generated an interest in more cost-effective designs of studies and more efficient use of the costly data generated. Fall control studies are a very well-used study design where cases of a disease are selected and compared to a selection of healthy controls. For an unusual disease, this is much more effective than following up a sizable amount of healthy individuals to ensure that enough disease cases occur during the follow-up. However, until recently, it was unusual to reuse already collected data from case-control studies. Our work develops methods that eliminate limitations and for case-control studies forward towards new and effective study designs. Our methods make it possible to calculate the prognosis or risk of other cancers using the data from case-control studies or from more cost-effective designs where the earliest cases are compared to the longest living controls. We focused on a number of different cancers where the costly information is collected / collected
    dose of radiation therapy and lung cancer, mammographic density and breast cancer, genetic biomarkers for lethal prostate cancer. As time and money is a limitation in itself, researchers continue to use case control and other designs for data collection. Data currently generated for these studies is currently not fully utilized. Our work is to develop methods and software that more cost-effectively utilize research data to estimate cancer risk and prognosis. This can in turn lead to a more optimal and more ethical use of the biological material that volunteers contributed to cancer research.
  • Design and analysis of more effective epidemiological studies for cancer research
    Swedish Cancer Society
    1 January 2015
    The major investments in the collection and measurement of biomarkers for cancer have generated an interest in more cost-effective designs of studies and more efficient use of the costly data generated. Fall control studies are a very well-used study design where cases of a disease are selected and compared to a selection of healthy controls. For an unusual disease, this is much more effective than following up a sizable amount of healthy individuals to ensure that enough disease cases occur during the follow-up. However, until recently, it was unusual to reuse already collected data from case-control studies. Our work develops methods that eliminate limitations and for case-control studies forward towards new and effective study designs. Our methods make it possible to calculate the prognosis or risk of other cancers using the data from case-control studies or from more cost-effective designs where the earliest cases are compared to the longest living controls. We focused on a number of different cancers where the costly information is collected / collected
    dose of radiation therapy and lung cancer, mammographic density and breast cancer, genetic biomarkers for lethal prostate cancer. As time and money is a limitation in itself, researchers continue to use case control and other designs for data collection. Data currently generated for these studies is currently not fully utilized. Our work is to develop methods and software that more cost-effectively utilize research data to estimate cancer risk and prognosis. This can in turn lead to a more optimal and more ethical use of the biological material that volunteers contributed to cancer research.
  • Swedish Research Council
    1 January 2015 - 31 December 2017
  • Swedish Research Council
    1 January 2013 - 31 December 2016

Employments

  • Professor Emeritus/Emerita, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2025-2027

Supervision

  • Supervision to doctoral degree

    • Benedicte Delcoigne, Efficient design and analysis of extended case-control studies, 2017
    • Myeongjee Lee, Effects of kinship and timing on family cancer risk, 2015
    • Mikael Hartman, Risk and prognosis of breast cancer among women at high risk of the disease, 2007
    • Monica Leu, Truncation and missing familial links in population-based registers, 2008
  • Other researchers who have defended a thesis

    • Nishan Lamichhane

News from KI

Events from KI